CM 101 - ChemomAb

Drug Profile

CM 101 - ChemomAb

Alternative Names: CM-101 - ChemomAb

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemomAb
  • Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic scleroderma
  • Preclinical Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis

Most Recent Events

  • 23 Nov 2017 Preclinical development in Idiopathic pulmonary fibrosis and primary sclerosing cholangitis is still underway in Israel
  • 20 Oct 2017 Pharmacodynamic data from preclinical trials in Non-alcoholic steatohepatitis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 30 Jul 2017 Phase-I clinical trials in Systemic scleroderma (In volunteers) in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top